comparemela.com

Latest Breaking News On - Pediatric growth hormone deficiency - Page 2 : comparemela.com

Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings

18.04.2024 - AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) - Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today . Seite 1

SwedenStockholmAndrew dauberPeter claytonEuropean congressInternational congressGrowth hormone research societySimilar annualized height velocityModerate pediatric growth hormone deficiencyPromising investigational safety recordPediatric growth hormone deficiency

Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings

AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic ca.

RussiaSwedenUkraineChicagoIllinoisUnited statesStockholmTexasErick hawkinsPeter claytonLumos pharmaJ clin endocrinolLisa millerAndrew dauberNasdaqPediatric endocrine society

Lumos Pharma Promotes Pisit "Duke" Pitukcheewanont, MD to Chief Medical Officer -January 04, 2024 at 04:07 pm EST

AUSTIN, Texas, Jan. 04, 2024 Lumos Pharma, Inc. , a late-stage biopharmaceutical company focused on therapeutics for rare diseases, has promoted Pisit “Duke” Pitukcheewanont, MD, known also.

TexasUnited statesLisa millerAscendis pharmaLos angelesLumos pharmaErick hawkinsPisit duke pitukcheewanontHuman growth foundationNasdaqKeck school of medicineGlobal clinical developmentUniversity of southern californiaLumos pharma incChief medical officerKeck school

Lumos Pharma Promotes Pisit "Duke" Pitukcheewanont, MD to Chief Medical Officer

AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutic.

TexasUnited statesLisa millerLumos pharmaLos angelesAscendis pharmaErick hawkinsPisit duke pitukcheewanontNasdaqHuman growth foundationKeck school of medicineGlobal clinical developmentLumos pharma incUniversity of southern californiaChief medical officerKeck school

Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency

21.11.2023 - Webinar to be Held December 6, 2023 at 1:30pm ESTAUSTIN, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) - Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency .

WashingtonUnited statesTexasChileLesliea soykaFernando cassorlaAndrew dauberLumos pharma incUmass memorial medical centerUmass chan medical schoolNasdaqChild researchUniversity of chileEndocrinology at children national medical centerInstitute of maternalHeld december

vimarsana © 2020. All Rights Reserved.